Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 221 UK small molecule drug companies below.
Light-activated small molecule therapies for oral cancer and wound care
LightOx is a biotechnology company developing light-activated small molecule therapeutics for cancer and infection. Its lead candidate LXD191 is a topically applied photosensitising compound targeting early-stage oral cancer and pre-cancerous lesions, activated by a specific wavelength of light to generate reactive…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Small molecule drugs targeting intrinsically disordered proteins in cancer
Kodiform Therapeutics is a drug discovery company developing first-in-class small molecule inhibitors against intrinsically disordered protein targets in cancer, a class historically considered undruggable due to the absence of stable binding pockets. The company uses intracellular antibody technology to identify and…
Anti-virulence drug discovery from natural bioactive compounds
Neem Biotech is a Wales-based drug discovery company developing novel non-traditional antimicrobial treatments derived from naturally inspired compounds. The company specialises in quorum sensing inhibitors and anti-biofilm agents, with programmes targeting wound infection and cystic fibrosis. Its discovery approach…
Oral small-molecule therapies targeting autoimmune disease pathways
SMIN Therapeutics is a biotechnology company developing oral medicines for autoimmune diseases. Its drug discovery platform studies interactions between proteins to identify therapeutic compounds, with an initial focus on the neonatal Fc receptor (FcRn), which regulates immunoglobulin G (IgG). The company is…
AI-enabled small molecule drug discovery
PharmEnable is a Cambridge-based drug discovery company developing novel small molecule therapeutics for targets that are inaccessible to biologics, including intracellular targets and those behind the blood-brain barrier. Its proprietary platform integrates AI and advanced medicinal chemistry to explore undercharted…
Clinical-stage anti-infectives targeting antimicrobial resistance and infectious disease
NovaBiotics is a clinical-stage biotechnology company developing first-in-class anti-infective therapies for difficult-to-treat infectious diseases, with a focus on antimicrobial resistance. Its pipeline is built on two proprietary platforms: an anti-infective peptide platform yielding antifungal and antibacterial…
Small molecule theranostics to improve transplant outcomes
Kairos Biotech is an early-stage biotechnology company developing proprietary small molecules and nanoscale-engineered binders for application in transplant diagnostics and targeted immunotherapy. The company's theranostic approach identifies molecules capable of detecting donor-specific alloreactivity and further…
Biopharmaceutics and dissolution consultancy for drug product development
Biowaived is a contract research organisation providing biopharmaceutics and dissolution expertise to pharmaceutical and biotechnology companies. The company offers consultancy and laboratory-based experimental services spanning dissolution method development, physicochemical characterisation of active pharmaceutical…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with…
In vitro skin penetration and dermal absorption contract research
An-eX Analytical Services is an independent contract research organisation specialising in in vitro dermal absorption and skin penetration science. The company provides human skin penetration and permeation studies conducted to OECD 428 and related guidelines, alongside in vitro release testing, analytical method…
Generic, branded and biosimilar medicines across global therapeutic areas
Viatris UK Healthcare is the UK subsidiary of Viatris Inc., a global pharmaceutical company formed in 2020 through the combination of Mylan and Pfizer's Upjohn division. Operating from sites in Hertfordshire, Cambridge, and Sandwich, Kent, the UK entity carries out formulation and device research and development,…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Sustained-release ocular drug delivery for retinal disease
Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery technologies for the treatment of serious retinal diseases. Its biodegradable hydrogel platform uses photo-crosslinking to form in-situ implants administered via intravitreal injection, enabling controlled release of biologics,…
Contract development and manufacturing of complex small molecule APIs and ADCs
Sterling Pharma Solutions is a contract development and manufacturing organisation specialising in complex small molecule active pharmaceutical ingredient development and cGMP manufacturing for the pharmaceutical and biotech industries. Capabilities include hazardous and high-potency chemistry, flow chemistry,…
Anti-cancer drug formulation and manufacturing technology development services
PTC Oncology is a contract research organisation specialising in the formulation and manufacturing technology development of anti-cancer drugs. The company supports pharmaceutical manufacturers, research centres, and academic institutions with pre-formulation studies, process design, scale-up, and analytical method…
Oncology biotech creation studio developing and spinning out cancer therapies
Cumulus Oncology is a company creation studio specialising in oncology drug discovery and development. The company identifies and sources novel cancer therapeutic assets from academic and commercial organisations, funds them, and incorporates them into newly created spin-out biotechs. Cumulus provides scientific…
Clinical-stage company developing treatments for cancer cachexia and muscle wasting
Actimed Therapeutics is a clinical-stage specialty pharma developing treatments for cancer cachexia and muscle wasting disorders, areas with significant unmet need and no globally approved therapies. Its lead programme has completed Phase 1 and received FDA IND approval, with a Phase 2b/3 trial planned in non-small…
Academic-industry translational research institute
The Milner Therapeutics Institute is a University of Cambridge biomedical research institute established to bridge academic science and pharmaceutical drug discovery. Founded in 2015 and based at the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, it operates both an in-house research programme and…